Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium
January 7th, 2019
Authorization extends patient recruitment base of European Phase II/III CORAL study, previously authorized in France.
Advicenne (Euronext: ADVIC), specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces today that it has received authorization from the Belgian health authority (FAMHP) to begin a pivotal Phase II/III CORAL clinical trial in cystinuria with its flagship drug candidate, ADV7103. The French pharmaceutical company also assesses its financial visibility at the close of 2018…